Published in Ocul Immunol Inflamm on October 16, 2009
Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist (2011) 2.05
The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) (2010) 1.29
Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med (2013) 1.03
Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how? Int Ophthalmol Clin (2014) 0.85
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Res (2015) 0.84
Future therapies of wet age-related macular degeneration. J Ophthalmol (2015) 0.84
Vitreous analysis in the management of uveitis. Mediators Inflamm (2012) 0.80
[Diagnostics and treatment of primary vitreoretinal lymphoma]. Ophthalmologe (2015) 0.80
Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics. Indian J Ophthalmol (2011) 0.77
Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes. Graefes Arch Clin Exp Ophthalmol (2015) 0.77
Enucleation of painful blind eye for refractory intraocular lymphoma after dose-limiting chemotherapy and radiotherapy. Ann Hematol (2012) 0.75
Intraocular Lymphoma Models. Ocul Oncol Pathol (2015) 0.75
[Special hematological diagnostics and therapy options for ocular lymphoma taking CNS involvement into account]. Ophthalmologe (2015) 0.75
Recent progress in the diagnosis and treatment of primary vitreoretinal lymphoma. Taiwan J Ophthalmol (2016) 0.75
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Neurolymphomatosis. Neuro Oncol (2003) 2.68
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol (2004) 2.21
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
Plasmapheresis for lupus retinal vasculitis. Arch Ophthalmol (2006) 2.13
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol (2005) 2.01
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology (2011) 1.85
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol (2006) 1.76
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol (2005) 1.75
Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology (2005) 1.69
Relapsing polychondritis: a clinical review. Semin Arthritis Rheum (2002) 1.68
Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology (2007) 1.66
Comparison of manual and automatic section positioning of brain MR images. Radiology (2006) 1.63
Orbital involvement in Bing-Neel syndrome. J Neuroophthalmol (2010) 1.63
Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm (2010) 1.62
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2011) 1.62
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Permanent alopecia after cranial irradiation: dose-response relationship. Int J Radiat Oncol Biol Phys (2004) 1.58
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Ocular pemphigus. J Am Acad Dermatol (2005) 1.56
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery (2002) 1.50
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer (2012) 1.43
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids (2013) 1.40
Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology (2007) 1.36
Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol (2005) 1.36
Impact of biofluid viscosity on size and sedimentation efficiency of the isolated microvesicles. Front Physiol (2012) 1.36
Etiology and management of idiopathic orbital inflammation. Am J Ophthalmol (2004) 1.33
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology (2005) 1.33
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res (2004) 1.30
BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res (2003) 1.29
Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol (2005) 1.28
Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin (2006) 1.25
MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One (2013) 1.25
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res (2004) 1.20
Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology (2002) 1.20
Primary intraocular lymphoma: A review. Semin Ophthalmol (2006) 1.19
Acute posterior multifocal placoid pigment epitheliopathy: outcome and visual prognosis. Retina (2009) 1.19
360 degrees iris-ciliary body B-cell lymphoma masquerading as post-cataract uveitis. Semin Ophthalmol (2004) 1.18
High-dose methotrexate for intraocular lymphoma. Clin Cancer Res (2003) 1.15
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging (2004) 1.14
The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther (2002) 1.14
Role of collagen-binding heat shock protein 47 and transforming growth factor-beta1 in conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci (2003) 1.14
Glaucoma and uveitis. Surv Ophthalmol (2012) 1.13
A new approach to the diagnosis and treatment of intravascular lymphoma. J Neurooncol (2003) 1.13
Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol (2007) 1.12
Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina (2007) 1.11
Anterior segment optical coherence tomography. Semin Ophthalmol (2010) 1.09
Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm (2008) 1.09
Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci (2003) 1.08
Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology (2005) 1.08
Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology (2003) 1.07
Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol (2010) 1.07
Scleritis therapy. Ophthalmology (2011) 1.07
Limbal stem cell transplantation in chronic inflammatory eye disease. Ophthalmology (2002) 1.07
Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology (2006) 1.07
High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol (2008) 1.06
Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol (2011) 1.05
Vogt-Koyanagi-Harada syndrome associated with bilateral serous macular detachments responsive to immunomodulatory therapy. Ophthalmic Surg Lasers Imaging (2009) 1.05
Sterile corneal melting and necrotizing scleritis after cataract surgery in patients with rheumatoid arthritis and collagen vascular disease. Semin Ophthalmol (2003) 1.04
The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol (2008) 1.04
Risk of hypotony in noninfectious uveitis. Ophthalmology (2012) 1.03
The spectrum of fundus autofluorescence findings in birdshot chorioretinopathy. J Ophthalmol (2010) 1.02
Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol (2013) 1.02
Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm (2004) 1.02
Subconjunctival bevacizumab for corneal neovascularization. Cornea (2008) 1.02
Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol (2007) 1.01
Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology (2008) 1.01
Neurological manifestations of Waldenström macroglobulinemia. Nat Clin Pract Neurol (2008) 1.01
Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol (2004) 1.01
Basal ganglia activity remains elevated after movement in focal hand dystonia. Ann Neurol (2004) 1.01
The cell-layer- and cell-type-specific distribution of GalNAc-transferases in the ocular surface epithelia is altered during keratinization. Invest Ophthalmol Vis Sci (2003) 1.01
Infliximab for the treatment of refractory scleritis. Br J Ophthalmol (2009) 1.01
Visual outcome in herpes simplex virus and varicella zoster virus uveitis: a clinical evaluation and comparison. Ophthalmology (2002) 1.00
Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry (2013) 1.00
Cancer associated retinopathy (CAR): An autoimmune-mediated paraneoplastic syndrome. Semin Ophthalmol (2006) 1.00
Hypopyon in patients with uveitis. Ophthalmology (2009) 0.99
Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm (2004) 0.99
Scleral necrosis in a patient with congenital erythropoietic porphyria. Cornea (2011) 0.98
Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol (2007) 0.97
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology (2012) 0.97
Successful treatment of idiopathic orbital inflammation with mycophenolate mofetil. Am J Ophthalmol (2005) 0.97
Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome. Ophthalmology (2003) 0.96
Novel diagnostic approaches in Bing-Neel syndrome. Clin Lymphoma Myeloma Leuk (2011) 0.96
Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol (2011) 0.96
Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm (2011) 0.96